Novo Nordisk A/S is a company quoted on the NYSE with the symbol NVO. As of 3rd February 2023, it had a market capitalisation of 307.66 billion US Dollars (USD). This value is calculated by taking the current share price of USD 140.96 and multiplying it by the number of outstanding shares which currently stand at 2,252,450,048. The market capitalisation has decreased over the past two days from 297.65 bln USD on 2nd February to its current level of 307.66 bln USD, representing a decrease of approximately 3.33%.
The stock price has dropped 1.99% today, closing at 140.96 after opening at 141.05 and reaching an intraday high of 141.96 and a low of 140.695 in today’s trading session on the NYSE exchange. Over the past 12 months, NVO’s stock price has increased from 94.75 on 3rd February 2022 to its current level of 140.96 representing an increase of 48%. The 50 day moving average for Novo Nordisk A/S stands at 135.45 and their 200 day moving average is 115.41 as per figures available for 2nd February 2023
Novo Nordisk A/S also reports earnings per share (EPS) figures for their last fiscal year ending December 31st 2022 which stand at 3.53 USD compared with 4 dollars reported in 2021 and 3 dollars reported in 2020 respectively . The P/E ratio stands at 39.93 times earnings which provides an indication that the stock is not particularly cheap but not overly expensive either considering its performance over the past 12 months.. Therefore it can be concluded that Novo Nordisk A/S appears to have a relatively stable financial situation despite recent declines in its share price and market capitalisation levels over the past few days
